Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in infant botulism.

Christine K Fox1, Corinne A Keet, Jonathan B Strober

  • 1Division of Child Neurology, UCSF School of Medicine, University of California-San Francisco, 500 Parnassus Avenue, San Francisco, CA 94143-0136, USA.

Pediatric Neurology
|February 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Housing mobility program effects on ambient fine particulate matter exposure and childhood asthma morbidity.

Annals of the American Thoracic Society·2026
Same author

Thrombectomy for Pediatric Large Vessel Occlusion Stroke With Mild Presenting Symptoms.

Neurology·2026
Same author

Using Quantitative EEG to Manage Blood Pressure in a Child With Carotid ECMO Cannulation: Case Report and Proof of Concept.

Journal of child neurology·2026
Same author

Multi-center study of long-term evolution of neuroimaging findings in PHACE syndrome.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026
Same author

Stroke Mimics in Children With Moyamoya Arteriopathy.

Stroke (Hoboken, N.J.)·2026
Same author

Striving toward quality metrics for pediatric stroke: time from door to diagnosis.

Frontiers in stroke·2026
Same journal

Corrigendum to Temporary Pacemaker in a Pediatric Guillain-Barré Case With Life-Threatening Bradyarrhythmia Pediatr Neurol 177 (2026) 109-110. doi: 10.1016/j.pediatrneurol.2026.01.015.

Pediatric neurology·2026
Same journal

Clinical Symptoms in Late Infantile and Juvenile Onset Neuronal Ceroid Lipofuscinosis Type 7 (CLN7 Disease).

Pediatric neurology·2026
Same journal

Examining Epilepsy in Angelman Syndrome: Insights From Caregiver-Reported Data in the Linking Angelman and Dup15q Data for Expanded Research Database.

Pediatric neurology·2026
Same journal

Impact of Postpandemic Pediatric Infection Rebound on Febrile Seizures: A Nationwide Cohort Study, 2013-2023.

Pediatric neurology·2026
Same journal

The Hidden Cost of Developmental and Epileptic Encephalopathy in Australia: Caregiver Quality of Life, Sleep, Depression, and Workforce Participation.

Pediatric neurology·2026
Same journal

A Novel Neonatal Brain Injury Score for Infants With Congenital Diaphragmatic Hernia.

Pediatric neurology·2026
See all related articles

Infant botulism, caused by botulinum toxins, has evolving understanding and treatments. A new human botulism immune globulin offers a specific therapy for affected infants.

Area of Science:

  • Microbiology
  • Toxicology
  • Pediatrics

Background:

  • Infant botulism, identified 30 years ago, involves botulinum toxins.
  • Clostridium baratii and Clostridium butyricum are now recognized as causative agents alongside Clostridium botulinum.
  • Therapeutic botulinum toxin use fuels research into toxin mechanisms.

Purpose of the Study:

  • To review the clinical presentation, diagnosis, and treatment of infant botulism.
  • To discuss the various organisms and toxins responsible for infant botulism.
  • To highlight the recent approval of a specific treatment for infant botulism.

Main Methods:

  • Review of existing literature on infant botulism.
  • Analysis of case reports involving unusual botulinum toxins.

Related Experiment Videos

  • Discussion of newly approved therapeutic interventions.

    • Main Results:

    • Understanding of botulinum toxins and their producing organisms has advanced.
    • Different botulinum toxin types may lead to varied clinical presentations in infants.
    • A specific treatment, human botulism immune globulin, is now available.

    Conclusions:

    • Infant botulism diagnosis and treatment have significantly evolved.
    • Newer causative agents and toxin types expand the scope of the disease.
    • The advent of human botulism immune globulin marks a major advancement in pediatric care for this condition.